Immunobiology of uveal melanoma
Martine J. Jager, Inge H.G. Bronkhorst, Jerry Y. Niederkorn
Uveal melanoma is the most common malignant intraocular tumor in adults. The malignancy of uveal melanoma is correlated with its capacity to metastasize to distant organs. Indeed, liver metastasis remains the leading cause of death in uveal melanoma patients. Although primary uveal melanoma can be effectively treated with surgery or radiotherapy, there is no known therapeutic modality with proven efficacy in prolonging life or ameliorating liver metastases. Sadly, the 5-year mortality rate for uveal melanoma patients has not changed in the past 30 years. Although uveal melanoma cells express tumor-specific antigens that can elicit immune responses, the tumors escape immune elimination due to the sanctuary provided by the immune privilege of the eye. Once uveal melanoma cells metastasize to the liver, they enter an immunologically hostile environment. However, mounting evidence suggests that uveal melanoma cells adopt many of the properties and mechanisms that contribute to immune privilege in the eye and thereby create ad hoc immune privilege at the metastatic site. Although uveal melanoma have multiple immune escape mechanisms, new insights into the nature of immune privilege offer glimmers of hope for the development of novel and effective immunotherapeutic strategies for treating this blinding and deadly neoplasm.
The Curated Reference Collection in Neuroscience and Biobehavioral Psychology
Elsevier Science Ltd.
https://doi.org/10.1016/B978-0-12-809324-5.01389-4
Immune defense
Immune surveillance
PD-1
T cell
Uveal melanoma
10.1016/B978-0-12-809324-5.01389-4
Dive into the research topics of 'Immunobiology of uveal melanoma'. Together they form a unique fingerprint.
Uveal melanoma Medicine & Life Sciences 100%
Immune Privilege Medicine & Life Sciences 49%
Tumor Escape Medicine & Life Sciences 11%
Neoplasm Metastasis Medicine & Life Sciences 10%
Neoplasm Antigens Medicine & Life Sciences 8%
Jager, M. J., Bronkhorst, I. H. G., & Niederkorn, J. Y. (2016). Immunobiology of uveal melanoma. In The Curated Reference Collection in Neuroscience and Biobehavioral Psychology (pp. 285-289). Elsevier Science Ltd.. https://doi.org/10.1016/B978-0-12-809324-5.01389-4
Immunobiology of uveal melanoma. / Jager, Martine J.; Bronkhorst, Inge H.G.; Niederkorn, Jerry Y.
The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. Elsevier Science Ltd., 2016. p. 285-289.
Jager, MJ, Bronkhorst, IHG & Niederkorn, JY 2016, Immunobiology of uveal melanoma. in The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. Elsevier Science Ltd., pp. 285-289. https://doi.org/10.1016/B978-0-12-809324-5.01389-4
Jager MJ, Bronkhorst IHG, Niederkorn JY. Immunobiology of uveal melanoma. In The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. Elsevier Science Ltd. 2016. p. 285-289 doi: 10.1016/B978-0-12-809324-5.01389-4
Jager, Martine J. ; Bronkhorst, Inge H.G. ; Niederkorn, Jerry Y. / Immunobiology of uveal melanoma. The Curated Reference Collection in Neuroscience and Biobehavioral Psychology. Elsevier Science Ltd., 2016. pp. 285-289
@inbook{0a75c4c008e84d6ba8e3c62f34363283,
title = "Immunobiology of uveal melanoma",
abstract = "Uveal melanoma is the most common malignant intraocular tumor in adults. The malignancy of uveal melanoma is correlated with its capacity to metastasize to distant organs. Indeed, liver metastasis remains the leading cause of death in uveal melanoma patients. Although primary uveal melanoma can be effectively treated with surgery or radiotherapy, there is no known therapeutic modality with proven efficacy in prolonging life or ameliorating liver metastases. Sadly, the 5-year mortality rate for uveal melanoma patients has not changed in the past 30 years. Although uveal melanoma cells express tumor-specific antigens that can elicit immune responses, the tumors escape immune elimination due to the sanctuary provided by the immune privilege of the eye. Once uveal melanoma cells metastasize to the liver, they enter an immunologically hostile environment. However, mounting evidence suggests that uveal melanoma cells adopt many of the properties and mechanisms that contribute to immune privilege in the eye and thereby create ad hoc immune privilege at the metastatic site. Although uveal melanoma have multiple immune escape mechanisms, new insights into the nature of immune privilege offer glimmers of hope for the development of novel and effective immunotherapeutic strategies for treating this blinding and deadly neoplasm.",
keywords = "Antigen, Complement, Eye, HLA, Immune checkpoints, Immune defense, Immune surveillance, Metastases, NK cells, PD-1, PD-L1, T cell, Tumor, Uveal melanoma",
author = "Jager, {Martine J.} and Bronkhorst, {Inge H.G.} and Niederkorn, {Jerry Y.}",
doi = "10.1016/B978-0-12-809324-5.01389-4",
booktitle = "The Curated Reference Collection in Neuroscience and Biobehavioral Psychology",
publisher = "Elsevier Science Ltd.",
T1 - Immunobiology of uveal melanoma
AU - Jager, Martine J.
AU - Bronkhorst, Inge H.G.
AU - Niederkorn, Jerry Y.
N2 - Uveal melanoma is the most common malignant intraocular tumor in adults. The malignancy of uveal melanoma is correlated with its capacity to metastasize to distant organs. Indeed, liver metastasis remains the leading cause of death in uveal melanoma patients. Although primary uveal melanoma can be effectively treated with surgery or radiotherapy, there is no known therapeutic modality with proven efficacy in prolonging life or ameliorating liver metastases. Sadly, the 5-year mortality rate for uveal melanoma patients has not changed in the past 30 years. Although uveal melanoma cells express tumor-specific antigens that can elicit immune responses, the tumors escape immune elimination due to the sanctuary provided by the immune privilege of the eye. Once uveal melanoma cells metastasize to the liver, they enter an immunologically hostile environment. However, mounting evidence suggests that uveal melanoma cells adopt many of the properties and mechanisms that contribute to immune privilege in the eye and thereby create ad hoc immune privilege at the metastatic site. Although uveal melanoma have multiple immune escape mechanisms, new insights into the nature of immune privilege offer glimmers of hope for the development of novel and effective immunotherapeutic strategies for treating this blinding and deadly neoplasm.
AB - Uveal melanoma is the most common malignant intraocular tumor in adults. The malignancy of uveal melanoma is correlated with its capacity to metastasize to distant organs. Indeed, liver metastasis remains the leading cause of death in uveal melanoma patients. Although primary uveal melanoma can be effectively treated with surgery or radiotherapy, there is no known therapeutic modality with proven efficacy in prolonging life or ameliorating liver metastases. Sadly, the 5-year mortality rate for uveal melanoma patients has not changed in the past 30 years. Although uveal melanoma cells express tumor-specific antigens that can elicit immune responses, the tumors escape immune elimination due to the sanctuary provided by the immune privilege of the eye. Once uveal melanoma cells metastasize to the liver, they enter an immunologically hostile environment. However, mounting evidence suggests that uveal melanoma cells adopt many of the properties and mechanisms that contribute to immune privilege in the eye and thereby create ad hoc immune privilege at the metastatic site. Although uveal melanoma have multiple immune escape mechanisms, new insights into the nature of immune privilege offer glimmers of hope for the development of novel and effective immunotherapeutic strategies for treating this blinding and deadly neoplasm.
KW - Antigen
KW - Complement
KW - Eye
KW - HLA
KW - Immune checkpoints
KW - Immune defense
KW - Immune surveillance
KW - Metastases
KW - NK cells
KW - PD-1
KW - PD-L1
KW - T cell
KW - Tumor
KW - Uveal melanoma
U2 - 10.1016/B978-0-12-809324-5.01389-4
DO - 10.1016/B978-0-12-809324-5.01389-4
BT - The Curated Reference Collection in Neuroscience and Biobehavioral Psychology
PB - Elsevier Science Ltd.